Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: Meta-analysis of five randomized double-blind clinical trials

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 165-171

  Féghali, Ramzi E L ^a   Nisse Durgeat, Sophie ^b   Asmar, Roland ^a  

^a Cardiovascular Institute   (France)

^b Laboratoires Takeda   (France)

Author keywords

Angiotensin II receptor antagonist; Antihypertensive diabetes; Blood pressure lowering; Candesartan cilexetil; Hypertension

Indexed keywords

CANDESARTAN HEXETIL; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL DESIGN; HUMAN; HYPERTENSION; META ANALYSIS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 34249895604     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Asmar R, Vol S, Pannier B, et al. 2001. High blood pressure and associated cardiovascular risk factors in France. J Hypertens, 19:1727-32.
2. Baguet JP, Nisse-Durgeat S, Mouret S, et al. 2006. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract, 60:391-8.
3. Bakris GL, Douglas J, Dworkin L, et al. 2000. Treatment of hypertension in adults with diabetes to preserve renal function: a consensus approach endorsed by the Scientific Advisory Board of the National Kidney Foundation. Am J Kidney Dis, 36:646-61.
4. Bengtsson C, Blohme G, Lapidus L, et al. 1984. Do antihypertensive drugs precipitate diabetes? Br Med J, 289:1495-7.
5. Berne C, Pollare TG, Lithell H. 1991. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care, 14:39-47.
6. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345:861-9.
7. Chaudhry SI, Krumholz HM, Foody JM. 2004. Systolic hypertension in older person. JAMA, 292:1074-80.
8. Chobanian AV, Bakris GL, Black HR, et al. 2003. The Seventh Report of the Joint National Committee on Preventions, detection, evaluation, and Treatment of High Blood Pressure. JAMA, 289:560-571.
9. Denolle T, Vaisse B, Perie F, et al. 2001. Feasibility of ambulatory blood pressure and home blood pressure measurement in therapeutic trials. Am J Hypertens, 14:42A.
10. Estacio RO, Jeffers BW, Hiatt WR, et al. 1998. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med, 338:645-52.
11. Furuhashi M, Ura N, Higashiura K, et al. 2003. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension, 42:76-81.
12. Gottlieb S, Leor J, Shotan A, et al. 2003. Comparison of effectiveess of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetics patients. Am J Cardiol, 92:1020-5.
13. Guidelines Subcommittee. 1999. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 17:151-83.
14. Guidelines Committee. 2003. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011-53.
15. Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351:1755-62.
16. [HDSG] Hypertension in Diabetes Study Group: Hypertension in Diabetes Study (HDS). 1993. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens, 11:319-25.
17. Imbs JL, Nisse-Durgeat S; French Collaborative Candesartan Study Group. 2005. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. Int J Clin Pract, 59:78-84.
18. Jaichenko J, Fudin R, Shostak A, et al. 1998. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and non diabetic chronic renal diseases: a need for reassessment. Nephron, 80:367-8.
19. Lewis EJ, Hunsicker LG, Clarke WR, et al. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345:851-60.
20. Lindholm LH, Hansson L, Ekbom T, et al. 2000. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens, 18:1671-5.
21. Lindholm LH, Ibsen H, Dahlof B, et al. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:1004-10.
22. Lindholm LH, Pearson M, Alaupovic P, et al. 2003. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens, 21:1563-74.
23. Lithell H, Hanson L, Skoog I, et al. 2003. The study on cognition and prognosis in the elderly (SCOPE): principle results of a randomized double-blind intervention trial. J Hypertens, 21:875-86.
24. Mancia G, Grassi G. 2002. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens, 20:1461-4.
25. Mogensen CE, Neldam S, Tikknen I, et al. 2000. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 321:1440-4.
26. Mancia G, Broun M, Castaigne A, et al. 2003. Outcomes with nifeldipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension, 41:431-6.
27. Niskanen L, Hedner T, Hansson L, et al.; CAPPP Study Group. 2001. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment: a sub-analysis of the Captopril Prevention Project. Diabetes Care, 24:2091-6.
28. Oksa A, Gajdos M, Fedelesova V, et al. 1994. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol, 23:79-86.
29. Padwal R, Laupacis A. 2004. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care, 27:247-55.
30. Parving HH, Lehnert H, Brochner-Mortensen J, et al. 2001. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 34:870-8.
31. Pershadsingh HA, Kurtz TW 2004. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care, 27:1015.
32. Pollare TG, Lithell H, Berne C. 1989. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med, 321:868-73.
33. Preston RA, Chung M, Gaffney M, et al. 2001. Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus. J Clin Pharmacol, 41:1215-24.
34. Scheen AJ. 2004. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs, 64:2537-65.
35. SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265:3255-64.
36. Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-44.
37. Staessen JA, Fagard R, Thijs L, et al. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 350:757-64.
38. Trenkwalder P, Dahl K, Lehtovirta M, et al. 1998. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press, 7:170-5.
39. Trost BN, Weidmann P. 1987. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens, 5 (Suppl):S81-104.
40. [UKPD 33] UK Prospective Diabetes Study Group 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
41. [UKPD 34] UK Prospective Diabetes Study Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352:854-65.
42. [UKPD 34] UK Prospective Diabetes Study Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ, 317:703-13.
43. [UKPDS 39] UK Prospective Diabetes Study Group. 1998. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ, 317:713-21.